- Home
- ISOU vs OCS Comparison
ISOU vs OCS Comparison
Compare ISOU & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ISOU | OCS |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Canada | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.3M | 732.4M |
| IPO Year | 2025 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ISOU | OCS |
|---|---|---|
| Price | $9.07 | $9.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $42.00 |
| AVG Volume (30 Days) | 135.4K | ★ 175.2K |
| Earning Date | 05-26-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $466.06 |
| Revenue Next Year | N/A | $479.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.19 | $9.00 |
| 52 Week High | $13.58 | $34.48 |
Technical Indicators
Market Signals| Indicator | ISOU | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 25.83 |
| Support Level | $7.80 | N/A |
| Resistance Level | $12.19 | $10.84 |
| Average True Range (ATR) | 0.54 | 0.60 |
| MACD | -0.18 | -0.12 |
| Stochastic Oscillator | 3.38 | 4.53 |
Price Performance
Historical ComparisonAbout ISOU IsoEnergy Ltd.
IsoEnergy Ltd is engaged in the acquisition, exploration, and evaluation of uranium properties in Canada. The company's project profile includes Geiger, Thorburn Lake, Full Moon, Edge, Collins Bay Extension, North Thorburn, 2Z Lake, and Madison. It operates in Canada, the United States, and Australia.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.